mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study,...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Dorit Fabricius, Carolin Ludwig, Judith Scholz, Immanuel Rode, Chrysanthi Tsamadou, Eva-Maria Jacobsen, Martina Winkelmann, Aline Grempels, Ramin Lotfi, Aleš Janda, Sixten Körper, Guido Adler, Klaus-Michael Debatin, Hubert Schrezenmeier, Bernd Jahrsdörfer
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2021-08-01
Saila:Vaccines
Gaiak:
heterologous vaccination regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs
RNA vaccines may facilitate rapid (re-) qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies
Sarrera elektronikoa:https://www.mdpi.com/2076-393X/9/8/918

Antzeko izenburuak

Antzeko izenburuak